Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies

Frontiers in Cell and Developmental Biology

Cell and Developmental Biology

Vaishali Bhardwaj¹  Stephen M. Ansell² 

[1] Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, United States;null;

关键词: myeloid-derived suppressor cells;    hematological malignancies;    tumor microenvironment;    t cells;    immunosuppression;   

DOI  :  10.3389/fcell.2023.1129343

 received in 2022-12-21, accepted in 2023-03-15,  发布年份 2023

来源: Frontiers

【 摘 要 】

Myeloid-derived suppressor cells (MDSCs) are pathologically activated neutrophils and monocytes that negatively regulate the immune response to cancer and chronic infections. Abnormal myelopoiesis and pathological activation of myeloid cells generate this heterogeneous population of myeloid-derived suppressor cells. They are characterized by their distinct transcription, phenotypic, biochemical, and functional features. In the tumor microenvironment (TME), myeloid-derived suppressor cells represent an important class of immunosuppressive cells that correlate with tumor burden, stage, and a poor prognosis. Myeloid-derived suppressor cells exert a strong immunosuppressive effect on T-cells (and a broad range of other immune cells), by blocking lymphocyte homing, increasing production of reactive oxygen and nitrogen species, promoting secretion of various cytokines, chemokines, and immune regulatory molecules, stimulation of other immunosuppressive cells, depletion of various metabolites, and upregulation of immune checkpoint molecules. Additionally, the heterogeneity of myeloid-derived suppressor cells in cancer makes their identification challenging. Overall, they serve as a major obstacle for many cancer immunotherapies and targeting them could be a favorable strategy to improve the effectiveness of immunotherapeutic interventions. However, in hematological malignancies, particularly B-cell malignancies, the clinical outcomes of targeting these myeloid-derived suppressor cells is a field that is still to be explored. This review summarizes the complex biology of myeloid-derived suppressor cells with an emphasis on the immunosuppressive pathways used by myeloid-derived suppressor cells to modulate T-cell function in hematological malignancies. In addition, we describe the challenges, therapeutic strategies, and clinical relevance of targeting myeloid-derived suppressor cells in these diseases.

【 授权许可】

Unknown   
Copyright © 2023 Bhardwaj and Ansell.